These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 21838767)
1. Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model. Oke JL; Stevens RJ; Gaitskell K; Farmer AJ Diabet Med; 2012 Feb; 29(2):266-71. PubMed ID: 21838767 [TBL] [Abstract][Full Text] [Related]
2. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048 [TBL] [Abstract][Full Text] [Related]
3. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change. Hirst JA; Stevens RJ; Farmer AJ PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212 [TBL] [Abstract][Full Text] [Related]
5. Glucose Awareness to Motivate and Enable Solutions (GAMES) in diabetes mellitus using flash glucose monitoring: A clinical programme. Yeoh E; Png D; Koh PL; Sum CF; Lim SC; Tan HH; Ubeynarayana CU; Subramaniam T Diabet Med; 2022 Jan; 39(1):e14733. PubMed ID: 34698420 [TBL] [Abstract][Full Text] [Related]
6. The frequency of testing for glycated haemoglobin, HbA1c, is linked to the probability of achieving target levels in patients with suboptimally controlled diabetes mellitus. Duff CJ; Solis-Trapala I; Driskell OJ; Holland D; Wright H; Waldron JL; Ford C; Scargill JJ; Tran M; Hanna FWF; Pemberton RJ; Heald A; Fryer AA Clin Chem Lab Med; 2018 Dec; 57(2):296-304. PubMed ID: 30281512 [TBL] [Abstract][Full Text] [Related]
7. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study. Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033 [TBL] [Abstract][Full Text] [Related]
8. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H Diabetes Res Clin Pract; 2015 Jun; 108(3):441-7. PubMed ID: 25795273 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial. Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903 [TBL] [Abstract][Full Text] [Related]
10. Use of haemoglobin A1c to detect impaired fasting glucose or Type 2 diabetes in a United Kingdom community based population. Kumaravel B; Bachmann MO; Murray N; Dhatariya K; Fenech M; John WG; Scarpello TJ; Sampson MJ; Diabetes Res Clin Pract; 2012 May; 96(2):211-6. PubMed ID: 22257419 [TBL] [Abstract][Full Text] [Related]
12. Effects of the Norfolk diabetes prevention lifestyle intervention (NDPS) on glycaemic control in screen-detected type 2 diabetes: a randomised controlled trial. Sampson M; Clark A; Bachmann M; Garner N; Irvine L; Howe A; Greaves C; Auckland S; Smith J; Turner J; Rea D; Rayman G; Dhatariya K; John WG; Barton G; Usher R; Ferns C; Pascale M; BMC Med; 2021 Aug; 19(1):183. PubMed ID: 34407811 [TBL] [Abstract][Full Text] [Related]
13. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Farmer AJ; Wade AN; French DP; Simon J; Yudkin P; Gray A; Craven A; Goyder L; Holman RR; Mant D; Kinmonth AL; Neil HA; Health Technol Assess; 2009 Feb; 13(15):iii-iv, ix-xi, 1-50. PubMed ID: 19254484 [TBL] [Abstract][Full Text] [Related]
14. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033 [TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618 [TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847 [TBL] [Abstract][Full Text] [Related]
17. Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia. Oei E; Samad N; Visser A; Chowdhury TA; Fan SL Diabet Med; 2016 Sep; 33(9):e17-20. PubMed ID: 26470840 [TBL] [Abstract][Full Text] [Related]
18. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study. Montvida O; Shaw JE; Blonde L; Paul SK Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes. Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039 [TBL] [Abstract][Full Text] [Related]
20. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]